Greenwich LifeSciences Flamingo-01 Manufacturing & Protocol Accepted by European Regulators
February 22, 2024 06:00 ET
|
Greenwich LifeSciences, Inc.
STAFFORD, Texas, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial,...
Arvinas Announces Chief Financial Officer Transition
February 20, 2024 16:05 ET
|
Arvinas Inc.
- Sean Cassidy leaving Arvinas as of February 29, 2024 - - Randy Teel, Ph.D. to assume the role of interim Chief Financial Officer - NEW HAVEN, Conn., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Arvinas,...
Celcuity Appoints Eldon Mayer as Chief Commercial Officer
February 20, 2024 07:05 ET
|
Celcuity Inc.
MINNEAPOLIS, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the...
Arvinas Announces First-in-Human Dosing of ARV-102, an Investigational PROTAC® Protein Degrader for Neurodegenerative Disease
February 20, 2024 07:00 ET
|
Arvinas Inc.
– ARV-102 is a novel oral PROTAC® protein degrader designed to cross the blood-brain barrier and target leucine-rich repeat kinase 2 (LRRK2) – – The Phase 1 trial of ARV-102 will evaluate safety,...
Blackford and b-rayZ Partner to Bring AI powered Breast Cancer Solutions to Healthcare Providers
February 20, 2024 05:30 ET
|
Blackford
Blackford and b-rayZ Partner to Bring AI powered Breast Cancer Solutions to Healthcare Providers
Arvinas and Pfizer’s Vepdegestrant (ARV-471) Receives FDA Fast Track Designation for the Treatment of Patients with ER+/HER2- Metastatic Breast Cancer
February 06, 2024 06:45 ET
|
Arvinas Inc.
-- Vepdegestrant is an investigational PROteolysis Targeting Chimera (PROTAC®) protein degrader designed to target and degrade the estrogen receptor (ER) protein -- NEW HAVEN, Conn. and NEW YORK,...
Arvinas to Present at 6th Annual Guggenheim Biotechnology Conference
February 01, 2024 16:30 ET
|
Arvinas Inc.
NEW HAVEN, Conn., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Europe Next-Generation Breast Cancer Diagnostic and Screening Market Analysis 2023-2032: Enhancing Early Detection and Personalized Care
January 25, 2024 11:00 ET
|
Research and Markets
Dublin, Jan. 25, 2024 (GLOBE NEWSWIRE) -- The "Europe Next-Generation Breast Cancer Diagnostic and Screening Market: Analysis and Forecast, 2023-2032" report has been added to ...
Italy Breast Cancer Diagnostics Market Sees Major Advancements and Strategic Approaches in 2024, Fueled by Emerging Technologies
January 25, 2024 09:27 ET
|
Research and Markets
Dublin, Jan. 25, 2024 (GLOBE NEWSWIRE) -- The "2024 Italy Breast Cancer Diagnostics Market - Country Database and Analysis - 2023 Supplier Shares and Strategies, 2023-2028 Volume and Sales Segment...
2024 Latin America Breast Cancer Diagnostics Market: 22-Country Database and Analysis, Supplier Shares and Strategies, Emerging Technologies, Latest Instrumentation & Growth Opportunities
January 24, 2024 05:25 ET
|
Research and Markets
Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The "2024 Latin America Breast Cancer Diagnostics Market - A 22-Country Database and Analysis, 2023 Supplier Shares and Strategies, 2023-2028 Volume and...